Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
We measured the effects of agonists and antagonists of metabotropic glutamate (mGlu) receptors (types 1 and 5) on NMDA‐induced depolarization of mouse cortical wedges in order to characterize the mGlu receptor type responsible for modulating NMDA responses. We also characterized a number of mGlu receptor agents by measuring [3 H]‐inositol phosphate (IP) formation in cortical slices and in BHK cells expressing either mGlu 1 or mGlu 5 receptors. (S)‐3,5‐dihydroxyphenylglycine (DHPG), an agonist of both mGlu 1 and mGlu 5 receptors, at concentrations ranging from 1 – 10 μ M, enhanced up to 105±15% the NMDA‐induced depolarization. Larger concentrations (100 – 300 μ M) of the compound were inactive in this test. When evaluated on [3 H]‐IP synthesis in cortical slices or in cells expressing either mGlu 1 or mGlu 5 receptors, DHPG responses (1 – 300 μ M) increased in a concentration‐dependent manner. (RS)‐2‐chloro‐5‐hydroxyphenylglycine (CHPG) and (S)‐(+)‐2‐(3′‐carboxybicyclo[1.1.1]pentyl)‐glycine (CBPG), had partial agonist activity on mGlu 5 receptors, with maximal effects reaching approximately 50% that of the full agonists. These compounds, however, enhanced NMDA‐evoked currents with maximal effects not different from those induced by DHPG. Thus the enhancement of [3 H]‐IP synthesis and the potentiation of NMDA currents were not directly related. 2‐methyl‐6‐(phenylethynyl)‐pyridine (MPEP, 1 – 10 μ M), a selective mGlu 5 receptor antagonist, reduced DHPG effects on NMDA currents. 7‐(hydroxyimino)cyclopropan[b]‐chromen‐1a‐carboxylic acid ethylester (CPCCOEt, 30 μ M), a preferential mGlu 1 receptor antagonist, did not reduce NMDA currents. These results show that mGlu 5 receptor agonists enhance while mGlu 5 receptor antagonists reduce NMDA currents. Thus the use of mGlu 5 receptor agents may be suggested in a number of pathologies related to altered NMDA receptor function. British Journal of Pharmacology (2001) 132, 799–806; doi:10.1038/sj.bjp.0703904
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Glutamate Receptor Ion Channels
Dingledine, R., Borges, K., Bowie, D., & Traynelis, S. F. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01394-2 · Cited by 3,554 · cited 1×
“…of neurotransmission and may be classi®ed, on the basis of their preferential agonists in N-methyl-D-aspartate (NMDA), (S) -a-amino -4 -bromo -3 -hydroxy -5 -isoxazolepropionic acid (AMPA) and kainate (KA) types (Collingridge & Lester, 1989; Hollmann & Heinemann, 1993; Dingledine et al., 1999).”
BackgroundRecent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Molecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543
Heteromeric NMDA receptors: molecular and functional distinction of subtypes
Monyer, H., Sprengel, R., Schoepfer, R., Herb, A., Higuchi, M., Lomeli, H., Burnashev, N., Sakmann, B., & Seeburg, P. H. (1992) · Science · doi:10.1126/science.256.5060.1217 · Cited by 2,541
Mice with Reduced NMDA Receptor Expression Display Behaviors Related to Schizophrenia
Mohn, A. R., Gainetdinov, R. R., Caron, M. G., & Koller, B. H. (1999) · Cell · doi:10.1016/s0092-8674(00)81972-8 · Cited by 1,075 · cited 1×
“A reduction in the function of the NMDA receptor complex has been associated with schizophrenia and other neuropsychiatric disorders (Carlsson et al., 1997; Mohn et al., 1999).”
BackgroundGasparini, F., Lingenhöhl, K., Stoehr, N., Flor, P. J., Heinrich, M., Vranesic, I., Biollaz, M., Allgeier, H., Heckendorn, R., Urwyler, S., et al. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00082-9 · Cited by 725 · cited 1×
“The involvement of mGlu 5 receptors in the enhancement of NMDA responses was supported also by the observation that MPEP (3 ± 10 mM), at concentrations that selectively interacted with mGlu 5 receptors (see: Figure 5 and Gasparini et al., 1999), completely prevented this enhancement.”
BackgroundLu, Y.-M., Jia, Z., Janus, C., Henderson, J. T., Gerlai, R., Wojtowicz, J. M., & Roder, J. C. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-13-05196.1997 · Cited by 634
Cited by
Metabotropic glutamate receptors: From the workbench to the bedside
Nicoletti, F., Bockaert, J., Collingridge, G. L., Conn, P. J., Ferraguti, F., Schoepp, D. D., Wroblewski, J. T., & Pin, J. P. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.022 · Cited by 653
Conn, P. J., Lindsley, C. W., & Jones, C. K. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.10.006 · Cited by 330
Mood disorders: Regulation by metabotropic glutamate receptors
Pilc, A., Chaki, S., Nowak, G., & Witkin, J. M. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.09.021 · Cited by 163
“Conversely, several lines of evidence suggest that mGlu5 receptor antagonists reduce NMDA receptor function in a number of brain areas [75].”
BackgroundNaie, K. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhg118 · Cited by 159
“Activation of mGlu5 results in the stimulation of dendritic protein synthesis (Huber et al., 2000), suppression of the calcium-activated potassium current (IAHP) and potentiation of NMDA receptor currents (Jia et al., 1998; Attucci et al., 2001; Mannaioni et al., 2001).”
BackgroundInfluentialPilpel, Y., Kolleker, A., Berberich, S., Ginger, M., Frick, A., Mientjes, E., Oostra, B. A., & Seeburg, P. H. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2008.160929 · Cited by 102
Esterlis, I., Holmes, S. E., Sharma, P., Krystal, J. H., & DeLorenzo, C. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.025 · Cited by 50
Wierońska, J. M., & Pilc, A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.010 · Cited by 23
The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
(2023) · International Review of Neurobiology · doi:10.1016/bs.irn.2022.10.007 · Cited by 8
Metadata
- Authors
- Attucci, S., Carlà, V, Mannaioni, G., & Moroni, F.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2001-02
- Volume
- 132
- Issue
- 4
- Pages
- 799-806
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2054419446
- Cited by
- 147
- References
- 7
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.